BIOMARIN PHARMACEUTICAL INC (BMRN)       82.87  -1.97 (-2.32%)

82.87  -1.97 (-2.32%)

US09061G1013 - Common Stock

News Image
11 days ago - Investor's Business Daily

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

News Image
11 days ago - BioMarin Pharmaceutical Inc.

BioMarin's Gene Therapy for Adults with Severe Hemophilia A, ROCTAVIAN™ (valoctocogene roxaparvovec), Assessed to Provide Substantial Cost Savings Per Patient in a Preliminary Independent Report

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the Institute for Clinical and Economic Review (ICER) released a Draft...

News Image
23 days ago - Investor's Business Daily

Neurocrine Leads 5 Stocks To Watch In Sickly Market

Neurocrine Biosciences leads five medical stocks showing resilience.

News Image
a month ago - BioMarin Pharmaceutical Inc.

First Gene Therapy for Adults with Severe Hemophilia A, BioMarin's ROCTAVIAN™ (valoctocogene roxaparvovec), Approved by European Commission (EC)

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that the European Commission (EC) has granted conditional marketing authorization...

News Image
2 months ago - InvestorPlace

7 Undervalued Biotech Stocks to Buy Before They Boom

Despite recession fears, biological sciences will never go out of style, thus benefitting these undervalued biotech stocks to buy.

News Image
2 months ago - BusinessInsider

BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET

SAN RAFAEL, Calif., July 20, 2022 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman...

News Image
2 months ago - BioMarin Pharmaceutical Inc.

BioMarin to Host Second Quarter 2022 Financial Results Conference Call and Webcast on Wednesday, August 3, at 4:30pm ET

/PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will...

News Image
2 months ago - Bloomberg

BioMarin’s Gene Therapy Nears European Market After US Setback

BioMarin Pharmaceutical Inc. expects European patients to begin receiving its gene therapy for a life-threatening blood-clotting disorder before the end of the year, raising the drugmaker’s hopes it can succeed where rival Bluebird Bio Inc. faltered.

News Image
3 months ago - Investor's Business Daily

Pharma Rally Continues As Pfizer, Amgen Look To Break Out, Pulling Rivals With Them

Four pharmaceutical stocks, including three biotech movers, are making big moves.

News Image
3 months ago - Market News Video

BMRN June 2023 Options Begin Trading

News Image
3 months ago - BusinessInsider

BioMarin Presents Findings from Studies of Valoctocogene Roxaparvovec, Investigational Gene Therapy, at the International Society on Thrombosis and Haemostasis (ISTH) 2022 Congress July 9-12, Incl...

Commitment to Advancing Care for People with Hemophilia A Demonstrated with Largest and Longest, Ongoing Clinical Development Program for any Gene...